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Bone size and shape is precisely modeled and remodeled throughout life to ensure the structure and integrity of the skeleton 1, 2 . Primary factors in temporal and spatial regulation of bone remodeling have been characterized 3, 4 . Angiogenesis is coupled with bone formation in these processes for proper bone homeostasis 5, 6 . A recent study revealed that a specific vessel subtype, CD31 hi Emcn hi vessels, couple angiogenesis and osteogenesis 7, 8 . However, the cellular and molecular regulation of angiogenesis during coupling to osteogenesis remains elusive.
During bone remodeling, osteoclast bone resorption is coupled with osteoblast bone formation by endocrine and paracrine factors to induce migration and differentiation of the precursors of these cell types 9, 10 . In response to stimulation with macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL), monocytes and macrophages first commit to the osteoclast lineage as tartrate-resistant acid phosphatase-positive (TRAP + ) mononuclear cells (preosteoclasts) 10 . Preosteoclasts subsequently fuse to form TRAP + multinuclear cells (osteoclasts) 10, 11 . Growth factors such as transforming growth factor-β (TGF-β) and insulin-like growth factor type 1 (IGF-1) are released from the bone matrix during osteoclast bone resorption to induce migration and differentiation of mesenchymal stem cells (MSCs) into osteoblasts for new bone formation 12, 13 .
During bone modeling, osteoclast bone resorption and osteoblast bone formation occur independently 1 . The cell signaling mechanisms that regulate bone modeling are less well understood, although studies in humans and mice with osteopetrosis with impaired osteoclast function suggest osteoclasts may promote osteogenesis independent of resorptive activity [14] [15] [16] [17] . There are abundant numbers of preosteoclasts on the periosteal bone surface, especially in regions associated with rapid growth 18, 19 . Of note, v-ATPase V0 subunit D2-deficient mice with failure of fusion of preosteoclasts show increased bone formation 16 . Recently, F4/80 + macrophages on periosteal and endosteal surfaces, termed 'OsteoMacs' , have also been shown to regulate in vitro mineralization of osteoblasts and are required for the maintenance of mature osteoblasts in vivo 20, 21 .
An adequate blood supply is critical for bone health by transporting nutrients, oxygen, minerals and metabolic wastes essential for maintaining proper osteoblastic bone matrix synthesis and mineralization 22, 23 . Cortical bone is enmeshed by capillaries that interact with a network of intracortical canals consisting of longitudinal Haversian canals and transversal Volkmann canals that link the periosteum and the endosteum 24, 25 . During modeling associated with growth, endothelial cells invade the cartilage at the growth plate region to form a vascular channel for nutrient supply and serve as a scaffold for new bone formation 6, 24 . Capillaries are also present at bone remodeling sites and help further couple bone resorption and bone formation 24, 26 .
Angiogenesis involves migration and proliferation of endothelial cells, capillary tube formation and MSC stabilization of newly formed tubes 27, 28 . Of note, the interaction of MSCs with endothelial cells further regulates angiogenesis by secretion of angiogenic growth factors, cytokines and other signaling molecules 29, 30 . PDGF-BB stimulates migration and angiogenesis of endothelia progenitor cells (EPCs) and MSCs 31, 32 . PDGF-BB is believed to mobilize cells of mesenchymal origin, stabilize newly formed vessels and orchestrate cellular components for osteoblast differentiation 33 . It has been reported that osteoclasts secrete PDGF-BB to induce migration of MSCs or osteoblasts [34] [35] [36] .
In this study, we report that preosteoclasts secrete PDGF-BB during bone modeling and remodeling to induce angiogenesis and thus proper osteogenesis. Depletion of PDGF-BB in the TRAP + cell lineage reduces angiogenesis in the bone marrow and periosteum with reduced bone formation. Inhibition of cathepsin K (CTSK) effectively increases preosteoclast numbers and levels of PDGF-BB, stimulating CD31 hi Emcn hi vessel and bone formation in OVX mice. Thus, PDGF-BB secreted by preosteoclasts stimulates angiogenesis, further supporting osteogenesis.
RESULTS

TRAP + cell deficiency impairs cortical bone formation
To examine the role of osteoclast-lineage cells in bone formation, we analyzed colony-stimulating factor-1 (CSF-1)-deficient (Csf1 −/− ) mice, which have TRAP + cell deficiency as CSF-1 is essential for the survival of monocyte-macrophage-lineage cells. Due to deficiency in osteoclast bone remodeling, a high volume of unmineralized bone 37 was formed in Csf1 −/− mice relative to their wild-type littermates (Fig. 1a,b) . Notably, the cortical bones of Csf1 −/− mice were extremely thin (Fig. 1a,b) . The periosteal perimeter of femoral diaphysis in the Csf1 −/− mice was significantly lower relative to that of their wild-type littermates (Fig. 1b) . TRAP staining of femur sections confirmed that there were no TRAP + cells on the periosteal bone surface in the Csf1 −/− mice (Fig. 1c,d ).
Coimmunostaining of CD31 and Emcn demonstrated that the number of CD31 hi Emcn hi cells in the periosteum of Csf1 −/− mice was significantly lower relative to that in their wild-type littermates (Fig. 1e,f) .
Postnatal cortical bone grows quickly during puberty, and the growth decreases gradually when approaching adulthood. We examined the numbers of preosteoclasts on the periosteal bone surface during postnatal growth through adulthood in wild-type mice. The number of periosteal preosteoclasts was very abundant at day 15 after birth, decreased by 45% by 1 month of age and by 78% by 3 months and was rarely detectable by 6 months (Fig. 1g,h) . Consistent with previous reports 18, 19 , periosteal TRAP + cells were largely mononuclear (Fig. 1c,g ). These observations suggest a potential role of preosteoclasts in cortical bone formation during skeletal modeling.
PDGF-BB from preosteoclasts induces MSC and EPC migration
To examine the potential molecular mechanism by which preosteoclasts regulate trabecular bone remodeling and periosteal bone modeling, we cultured monocytes and macrophages to differentiate them into preosteoclasts and osteoclasts, as evidenced by TRAP-positive staining and the number of nuclei ( Supplementary  Fig. 1a) . We collected the conditioned media of monocytes and macrophages, preosteoclasts and osteoclasts cultured with or without bone slices. Conditioned medium from preosteoclasts induced significantly more MSC migration relative to control conditioned medium from monocytes and macrophages, and the migration was further stimulated when a bone slice was added to the culture (Fig. 2a) . Conditioned medium from osteoclasts without the bone slice had very little effect on MSC migration, indicating that the unique factor for promoting MSC migration was secreted specifically in preosteoclast-conditioned medium (Fig. 2a) . To identify this secreted factor, we tested neutralizing antibodies against TGF-β1, TGF-β2, TGF-β3, IGF-1, IGF-II, PDGF-AA and PDGF-BB, as well as noggin, in the conditioned media. Only the antibody against PDGF-BB abolished the preosteoclast-conditioned medium-induced migration (Fig. 2b) . TGF-β1-neutralizing antibody inhibited the migration induced by the osteoclast bone resorption-conditioned medium (Fig. 2b) , consistent with our previous report 12 . ELISA analysis confirmed that preosteoclasts secreted PDGF-BB and adding a bone slice enhanced the secretion, whereas osteoclasts with or without bone slice a Csf1 npg had significantly less secretion of PDGF-BB as compared to preosteoclasts (Fig. 2c) . Maturation of osteoclasts and their bone resorption activities were reflected by elevation of C-terminal telopeptide of type 1 collagen (CTX) concentrations in conditioned media (Fig. 2d) .
Western blot analysis of conditioned media from preosteoclasts confirmed that PDGF-BB, not PDGF-AA, was present (Fig. 2e) . PDGF-BB is known to induce migration of EPCs and promote angiogenesis 31 . Indeed, conditioned medium from preosteoclasts also induced significantly more EPC migration than the control conditioned medium from monocytes and macrophages (Fig. 2f) . The PDGF-BB-neutralizing antibody abolished the preosteoclastconditioned medium-induced EPC migration (Fig. 2f) . During osteoclastogenesis, preosteoclasts undergo fusion for osteoclast maturation and bone resorption. PDGF-BB secretion decreased gradually during fusion of preosteoclasts, as determined by ELISA ( Supplementary  Fig. 1b) . Coimmunostaining of TRAP + cells with PDGF-BB from cultured cells and mouse bone sections demonstrated that mature osteoclasts and monocytes and macrophages were largely PDGF-BB negative (Supplementary Fig. 1c,d) . Thus, our results suggest that preosteoclasts before osteoclast maturation secrete PDGF-BB to recruit MSCs and EPCs. Also, our data suggest that the presence of PDGF-BB in osteoclast cultures reported by other groups [34] [35] [36] is probably the result of contamination with preosteoclasts or premature osteoclasts. Furthermore, coimmunostaining demonstrated that TRAP + preosteoclasts on both periosteal and endosteal bone surfaces are not F4/80 + OsteoMacs (Supplementary Fig. 2a) , and F4/80 + OsteoMacs are PDGF-BB − cells (Supplementary Fig. 2b ).
PDGF-BB from preosteoclasts induces bone formation in mice
We then examined the function of PDGF-BB secreted by preosteoclasts in bone remodeling and periosteal bone formation. We crossed Pdgfbfloxed mice (Pdgfb flox/flox mice) with TRAP-Cre mice to generate mice with deletion of Pdgfb in the TRAP + cell lineage (Pdgfb −/− mice). The trabecular bone volume and thickness, cortical bone thickness and periosteal perimeter were all lower in the Pdgfb −/− mice relative to their Pdgfb flox/flox littermates (Fig. 3a) . The reduction of trabecular bone mass and cortical bone formation was not associated with expression of TRAP-Cre or Pdgfb flox allele alone (Supplementary Fig. 3 ). Calcein double labeling confirmed that Pdgfb −/− mice had less bone formation in both trabecular and cortical bone as compared to their Pdgfb flox/flox littermates (Fig. 3b) .
Coimmunostaining demonstrated that many TRAP + cells were positive for PDGF-BB in both trabecular bone and periosteum of Pdgfb flox/flox mice, but we rarely observed such cells in Pdgfb −/− mice (Fig. 3c) . The number of TRAP + cells on trabecular and periosteal bone surfaces and serum CTX concentrations were not different in Pdgfb −/− mice relative to their Pdgfb flox/flox littermates (Fig. 3c,d ), indicating that specific deficiency of PDGF-BB in TRAP + cells does not markedly affect osteoclast bone resorption. Of note, PDGF-BB concentrations in both bone marrow and peripheral blood were significantly lower and bone marrow vascular endothelial growth factor (VEGF) concentrations were also significantly lower in Pdgfb −/− mice than in their Pdgfb flox/flox littermates (Fig. 3e) . The bone marrow PDGF-BB concentration was lowered by 72.6% in Pdgfb −/− mice relative to their Pdgfb flox/flox littermates ( Fig. 3e and Supplementary Fig. 4a ). Endothelial cells also express PDGF-BB 38 . We therefore further analyzed the relative contribution of PDFG-BB produced in the bone marrow by preosteoclasts and endothelial cells. We found that the PDGF-BB amount in sorted endothelial cells (CD31 + CD45 − Ter119 − cells) constituted about 46.0% of total bone marrow PDGF-BB protein in Pdgfb −/− mice (Supplementary Fig. 4b) . The results indicate that bone marrow PDGF-BB arises primarily from TRAP + cells (72.6%), with 12.6% from endothelial cells and 14.8% from the rest of the bone marrow cells (Supplementary Fig. 4c ).
Microphil-perfused angiography showed that vessel volume and surface area were significantly lower in Pdgfb −/− mice than in their Pdgfb flox/flox littermates (Fig. 3f) . Pdgfb −/− mice had significantly lower numbers of CD31 hi Emcn hi endothelial cells in both marrow and periosteum as compared to their Pdgfb flox/flox littermates (Fig. 3g,h) . Pdgfb −/− mice had less proliferation of endothelial cells in metaphysis versus their Pdgfb flox/flox littermates (Fig. 3i) (Fig. 3j) further suggest that the lower degree of angiogenesis is related to less osteoblast bone formation. Taken together, these results suggest that PDGF-BB secreted by preosteoclasts stimulates angiogenesis and bone formation.
CTSK inhibition induces PDGF-BB secretion in preosteoclasts Pycnodysostosis is a rare genetic osteopetrotic disease due to mutations in the CTSK gene 39 . CTSK inhibition is under active investigation as a pharmacotherapy for osteoporosis. Preclinical and clinical data have noted that CTSK inhibition impairs osteoclast bone resorption but also increases numbers of preosteoclasts and osteoclasts and bone formation [40] [41] [42] [43] . Preosteoclasts and osteoclasts from Ctsk −/− mice lack normal apoptosis and senescence and exhibit overgrowth both in vitro and in vivo, which has been well characterized in a previous study 40 .
We therefore examined whether a CTSK inhibitor enhances secretion of PDGF-BB by preosteoclasts to promote angiogenesis and bone formation. We prepared conditioned media from preosteoclasts from Ctsk −/− mice and their wild-type littermates and examined their effects on migration of MSCs and EPCs by the transwell migration assay. The conditioned media from preosteoclasts with either inhibition of CTSK activity or gene deletion of Ctsk had higher concentrations of PDGF-BB protein ( Supplementary Fig. 5a ) and induced significantly more MSC and EPC migration versus conditioned medium from vehicletreated wild-type preosteoclasts, and the elevated cell migration was npg abolished by a PDGF-BB-neutralizing antibody ( Supplementary  Fig. 5b,c) . Coimmunostaining of TRAP and PDGF-BB in longitudinal femur sections revealed that the number of TRAP + PDGF-BB + cells was higher in the trabecular bone and periosteum in Ctsk −/− mice and wild-type mice treated with a CTSK inhibitor, L-006235 (L-235) 44 , than in vehicle-treated wild-type mice (Fig. 4a) . PDGF-BB concentrations in both bone marrow and peripheral blood were significantly higher and bone marrow VEGF concentration was also higher in these mice compared to their vehicle-treated wild-type counterparts ( Fig. 4b) , suggesting more angiogenesis. Vessel volume and surface area in bone marrow, as well as CD31 hi Emcn hi cell numbers in both bone marrow and periosteum, were significantly higher in Ctsk −/− mice and L-235-treated wild-type mice than in vehicle-treated wild-type mice ( Fig. 4c-e) . The trabecular bone volume and number, cortical bone thickness and periosteal perimeter were all higher in Ctsk −/− mice and L-235-treated wild-type mice relative to vehicle-treated wild-type mice ( Supplementary Fig. 6a,b) . Calcein double labeling confirmed that Ctsk −/− mice and L-235-treated wild-type mice had more bone formation in both trabecular and cortical bone versus vehicle-treated wild-type mice (Supplementary Fig. 6c ). The higher osteocalcin + cell numbers and serum osteocalcin concentration in Ctsk −/− mice and L-235-treated wild-type mice than in vehicle-treated wild-type mice ( Supplementary Fig. 6d ,e) indicate more osteoblast bone formation.
To validate that CTSK inhibitor-stimulated bone formation was mediated by increased angiogenesis and PDGF-BB secretion by preosteoclasts, we treated Pdgfb −/− mice with L-235. In Pdgfb −/− mice, the CTSK inhibition did not increase PDGF-BB and VEGF concentrations in either bone marrow or peripheral blood (Fig. 4f) . As expected, CTSK inhibition did not increase vessel volume and surface area, CD31 hi Emcn hi cell numbers or proliferation of metaphyseal endothelial cells in Pdgfb −/− mice (Fig. 4g,h ). CTSK inhibition did not increase cortical bone thickness and periosteal perimeter (Fig. 4i) and only moderately increased trabecular bone volume and number in Pdgfb −/− mice (Fig. 4i) . The inhibitor did not increase serum osteocalcin concentration in Pdgfb −/− mice, whereas levels of CTX in serum were lower in Pdgfb −/− mice and their wild-type littermates (Fig. 4j) . These results reveal that inhibition of CTSK increases secretion of PDGF-BB to enhance angiogenesis for bone formation. 
VEGF (pg ml npg PDGF-BB from preosteoclasts induces angiogenesis via focal adhesion kinase To examine the signaling mechanisms of PDGF-BB in promotion of angiogenesis-coupled bone formation, we prepared conditioned media from preosteoclasts or monocytes and macrophages or control medium to culture EPCs, MSCs or both in co-culture. Preosteoclast-conditioned medium induced EPC tube formation. Co-culture with MSCs significantly enhanced the EPC tube formation. whereas addition of PDGF-BB-neutralizing antibody attenuated the effect (Fig. 5a,b) . Activation of focal adhesion kinase (FAK) is known to mediate cell migration and angiogenesis 45 . Western blot analysis showed that preosteoclastconditioned medium induced phosphorylation of platelet-derived growth factor receptor-β (PDGFR-β) in both MSCs and EPCs by 5 min after incubation and peaked at 15 min (Fig. 5c) . Phosphorylation of its downstream components phosphatidylinositol 3-kinase (PI3K), Akt and FAK also peaked at 15 min (Fig. 5c) . Notably, the PDGFR inhibitor AG1296 blocked phosphorylation of PDGFR and the rest of the downstream kinases, the PI3K inhibitor LY294002 blocked phosphorylation of PI3K, Akt and FAK, and the Akt inhibitor MK2206 blocked phosphorylation of Akt and FAK, whereas the FAK inhibitor Y15 blocked only phosphorylation of FAK (Fig. 5d) . Independent inhibition of all components of this pathway was sufficient to block preosteoclast-conditioned medium-induced tube formation of MSC and EPC co-culture and migration of MSCs and EPCs (Fig. 5e,f) .
The results indicate that Akt-dependent activation of FAK signaling mediates PDGF-BB-induced cell migration and angiogenesis. Sphingosine-1-phosphate (S1P), the product of phosphorylation of sphingosine by sphingosine kinase 1 (Sphk1), stimulates osteoblast differentiation and function 46, 47 . S1P and Sphk1 production is increased during RANKL-induced osteoclastogenesis 46, 47 . Moreover, deletion of Ctsk increases Sphk1 expression and S1P secretion in osteoclasts 48 . S1P secretion and Sphk1 expression were lower in preosteoclasts of npg Pdgfb −/− mice than in preosteoclasts of age-matched Pdgfb flox/flox mice (Fig. 5g) , indicating S1P action is downstream of PDGF-BB. Indeed, Sphk1 expression and secreted S1P concentration were significantly higher in preosteoclasts and osteoclasts than in monocytes and macrophages (Fig. 5h) , consistent with the previous report 46 . Moreover, Sphk1 and S1P production were significantly higher in L-235-treated wild-type preosteoclasts or preosteoclasts from Ctsk −/− mice than in vehicle-treated wild-type preosteoclasts (Fig. 5i) . Preosteoclastconditioned medium induced alkaline phosphatase activity and matrix mineralization of MSCs (Fig. 5j) . The S1P 1,3 antagonist VPC23019 reduced osteoblast differentiation (Fig. 5j) . However, VPC23019 could not inhibit the preosteoclast-conditioned medium-induced migration of MSCs or EPCs (Supplementary Fig. 5b,c) . Altogether, our results show that PDGF-BB induces Akt/FAK-dependent angiogenesis in coupling osteogenesis by S1P signaling.
Increasing PDGF-BB attenuates bone loss in OVX mice
Postmenopausal osteoporosis is associated with increased osteoclastic bone resorption and decreased angiogenesis [49] [50] [51] . To examine the role of PDGF-BB in postmenopausal osteoporosis, we generated OVX mice, which had significantly smaller uterus size and lower uterus weight (Supplementary Fig. 7a,b) , as well as significantly lower trabecular bone volume, thickness and number and cortical thickness, compared to sham-operated (sham) mice (Supplementary Fig. 7c,d) . PDGF-BB concentrations in both bone marrow and peripheral blood and the VEGF concentration in bone marrow were significantly lower in OVX mice than in sham mice (Fig. 6a) . Microphil-perfused angiography demonstrated that vessel volume and surface area were significantly lower in OVX mice than in sham mice (Fig. 6b) . As expected, OVX mice had significantly higher numbers of osteoclasts compared to sham mice (Fig. 6c) . Of note, the osteoclasts were largely negative for PDGF-BB in the bone marrow from OVX mice, whereas periosteal preosteoclasts were positive for PDGF-BB (Fig. 6c) . Similarly, CD31 hi Emcn hi cell numbers were significantly lower in marrow but higher in periosteum in OVX mice compared to sham mice (Fig. 6d) . There was also less proliferation of endothelial cells in metaphysis in OVX mice than in sham mice (Supplementary Fig. 7e ).
We then examined whether increasing PDGF-BB abundance could be an effective potential therapy for postmenopausal osteoporosis. We treated OVX mice with either local injection of PDGF-BB in the femur or systemic delivery of L-235. PDGF-BB concentrations were significantly increased in bone marrow of OVX mice treated with either PDGF-BB or L-235, but increased only in peripheral blood after treatment with L-235, compared to vehicle-treatment concentrations npg (Fig. 6e) . Marrow VEGF concentrations were also increased in the PDGF-BB and L-235 groups compared to the vehicle group (Fig. 6e) . Microphil-perfused angiography demonstrated that OVX mice treated with either PDGF-BB or L-235 had significantly increased vessel volume and surface area in bone marrow compared to vehicle-treated mice (Fig. 6f) . Bone marrow injection of PDGF-BB significantly increased CD31 hi Emcn hi cell numbers in bone marrow only, whereas the CTSK inhibitor L-235 significantly increased CD31 hi Emcn hi cell numbers in both marrow and periosteum compared to vehicle treatment (Fig. 6g) . There was also more proliferation of endothelial cells in metaphysis in the PDGF-BB and L-235 groups compared to the vehicle group (Supplementary Fig. 8a) . Treatment of OVX mice with either PDGF-BB or L-235 substantially increased trabecular bone volume, thickness and number relative to vehicle treatment ( Supplementary  Fig. 8b ). The cortical bone thickness was increased and endosteal perimeter decreased markedly with administration of either PDGF-BB or L-235 (Supplementary Fig. 8b ). Calcein double labeling confirmed increased trabecular bone formation with administration of either PDGF-BB or L-235 (Fig. 6h) . Periosteal bone formation and periosteal perimeter were increased with L-235, but not with PDGF-BB, probably owing to bone marrow local injection ( Fig. 6h and Supplementary  Fig. 8b ). Serum osteocalcin concentrations were higher with both treatments and CTX concentrations were lower with L-235 compared to vehicle treatment (Fig. 6i) . Taken together, these results show that OVX-induced bone loss in mice results in a lower degree of PDGF-BB secretion and bone formation. Either local PDGF-BB administration or stimulation of preosteoclast secretion of PDGF-BB by systemic CTSK inhibition can temporally increase angiogenesis and spatially promote bone formation by coupling angiogenesis with osteogenesis.
DISCUSSION
Our study reveals that preosteoclasts secrete PDGF-BB to recruit EPCs and MSCs to promote angiogenesis during its coupling with osteogenesis. PDGF-BB secreted by preosteoclasts determines the temporospatial vessel formation needed for the subsequent bone resorption and new bone formation (Fig. 6j) . Vessel formation influences the microenvironment for differentiation of osteoprogenitors 5, 6 . A recent study identified a specific CD31 hi Emcn hi vessel subtype with distinct morphological and molecular properties and location. The relative abundance of the CD31 hi Emcn hi vessels is associated with bone formation or bone loss 7, 8 . We found that PDGF-BB secreted by preosteoclasts induces formation of the CD31 hi Emcn hi vessel subtype to promote the coupling of angiogenesis with bone formation. Notably, concentrations of PDGF-BB are substantially decreased in both bone marrow and peripheral blood after OVX-induced bone loss in mice, and CD31 hi Emcn hi vessels are also decreased in the bone marrow. Increasing maturation of osteoclasts from preosteoclasts reduces PDGF-BB abundance in ovariectomized mice, probably affecting bone formation. Knockout of Ctsk or injection of its inhibitor effectively increases the concentrations of PDGF-BB. In particular, treatment with a CTSK inhibitor increases angiogenesis, including CD31 hi Emcn hi vessels, and bone formation in ovariectomized mice. Our finding of preosteoclast-induced angiogenesis represents a potential therapeutic target for bone loss, particularly for postmenopausal osteoporosis. Cortical bone is a compact bone tissue that provides mechanical support for the body weight and makes up 80% of the weight of the human skeleton 2, 52 . In modeling, bone grows in both length and width, whereas in remodeling bone mass is homeostastically maintained 2, 52 . Longitudinal growth is achieved through endochondral ossification at the growth plate, as has been studied extensively 53 . However, little is known about the mechanisms that regulate the width of bone, which is determined mainly by periosteal cortical bone formation. We found that periosteal preosteoclasts function as signaling cells by secreting PDGF-BB to promote periosteal bone formation. However, the periosteal TRAP + cells expressing PDGF-BB are not F4/80 + OsteoMacs. Preosteoclasts have been observed previously in aquatic vertebrate skeleton 54, 55 and on the periosteal surface of cortical bone of mammals 18, 19 . Preosteoclasts exhibit limited bone resorption but are present on the bone surface to direct osteogenesis.
The periosteum is a microvascularized connective tissue covering the outer surface of the cortical bone 56 , a special microenvironment that could resemble a unique marrow for cortical bone modeling and growth. PDGF-BB from TRAP + preosteoclasts residing on the bone surface is able to temporally and spatially coordinate angiogenesis during bone growth, modeling and remodeling. Preosteoclast-conditioned medium induces migration of MSCs and EPCs, and MSCs enhance tube formation in in vitro assays. PDGF-BB from periosteal preosteoclasts stimulates secretion of S1P to also promote bone formation, further coupling angiogenesis to bone formation in the periosteal environment. Modeling of trabecular bone could also be modulated by preosteoclasts via a similar mechanism, whereas in trabecular bone remodeling, two distinct factors are employed: TGF-β1 activation during bone remodeling recruits MSCs for bone formation 12 and PDGF-BB secreted by preosteoclasts prepares angiogenesis for subsequent bone formation in addition to recruitment of MSCs. Indeed, PDGF-BB has been widely used for bone regeneration and fracture healing 57, 58 and the ability of PDF-BB to direct cortical bone formation could be the cellular mechanism by which it achieves these clinical effects.
CTSK is a cysteine proteinase and is highly expressed in osteoclasts. It is responsible for bone matrix protein degradation during bone resorption 59 . The selective CTSK inhibitors decrease osteoclastic bone resorption activity by preventing the degradation of bone matrix proteins 60 . Deletion of Ctsk specifically in osteoclasts increases secretion of S1P for bone formation during bone remodeling 48 . The CTSK inhibitor has also been shown to increase cortical dimension in mice, monkeys and humans and has been histomorphometrically demonstrated to stimulate periosteal bone formation of the long bones in preclinical models [41] [42] [43] . Notably, in Ctsk −/− mice and wild-type mice treated with a CTSK inhibitor, the number of periosteal preosteoclasts and the levels of PDGF-BB in the periosteum are markedly increased. Taken together, the genetic and pharmacological findings demonstrate that stimulation of secretion of PDGF-BB by preosteoclasts may enhance the recruitment of EPCs and MSCs and is a potential therapeutic target for periosteal cortical defects and osteoporosis.
METHODS
Methods and any associated references are available in the online version of the paper. We generated Ctsk −/− offspring and their wild-type littermates by crossing two heterozygote strains as described 62 . We analyzed male mice at 1 month of age, except as noted in specific experiments. We treated 4-week-old wild-type male mice and 6-week-old Pdgfb flox/flox and Pdgfb −/− male mice daily with either vehicle or 50 mg kg −1 b.w. L-235 (Merck) for 30 d. L-235 was administered orogastrically in a 0.5% Methocel (w/v) suspension via a feeding tube.
We determined the genotype of the mice by PCR analyses of genomic DNA isolated from mouse tails using the following primers: Csf1 op allele forward, 5′-TGCTAACCTCGTGGTTCCTG-3′ and reverse, 5′-GTTAGC ATTGGGGGTGTTGT-3′; TRAP-directed Cre forward, 5′-ATATCTCACGTAC TGACGGTGGG-3′ and reverse, 5′-CTGTTTCACTATCCAGGTTACGG-3′; loxP Pdgfb allele forward, 5′-GGGTGGGACTTTGGTGTAGAGAAG-3′ and reverse, 5′-GGAACGGATTTTGGAGGTAGTGTC-3′; Ctsk forward, 5′-GC CACACCCACACCCTAGAAG-3′ and reverse, 5′-ACAAGTGTACATTCCC GTACC-3′.
For ovary removal surgery, 3-month-old C57BL/6 female mice were generally anesthetized and subjected to either a sham operation (Sham) or bilateral ovariectomy (OVX). We randomly divided mice into five groups: Sham, OVX, OVX + vehicle, OVX + PDGF-BB and OVX + L-235. For OVX + PDGF-BB group, recombinant mouse PDGF-BB (1 µg; Pepro Tech) was delivered into the bone marrow cavity of the OVX mice from the medial side of the patellar tendon using 0.5-ml syringes with 27-gauge needles. The treatment was conducted once a month with the first injection at the same day of OVX. For OVX + L-235 group, L-235 (50 mg kg −1 b.w.) was delivered orogastrically into OVX mice. The treatment was conducted daily for 2 months. All mice were sacrificed at the age of 5 months. Whole-blood samples were collected by cardiac puncture immediately after euthanasia, and serum samples obtained by centrifugation (1,500 r.p.m., 15 min) were stored at −80 °C before analyses. Uteri were isolated and weighed to confirm the effects of ovariectomy. Femora and tibia were also collected.
We maintained all animals in the Animal Facility of the Johns Hopkins University School of Medicine. The experimental protocol was reviewed and approved by the Institutional Animal Care and Use Committee of Johns Hopkins University, Baltimore, MD, USA.
mCT analysis. Femora were dissected from mice, fixed overnight in 70% ethanol and analyzed by high-resolution µCT (Skyscan 1172, Skyscan) 13, 63, 64 . The scanner was set at a voltage of 49 kV, a current of 200 µA and a resolution of 8.7 µm per pixel. We used image reconstruction software (NRecon v1.6), data analysis software (CTAn v1.9) and three-dimensional model visualization software (µCTVol v2.0) in order to analyze the parameters of the diaphyseal cortical bone and the distal femoral metaphyseal trabecular bone. We established cross-sectional images of the femora to perform two-dimensional morphometric analyses of the cortical bone and three-dimensional histomorphometric analysis of the trabecular bone. Trabecular bone region of interest (ROI) was drawn starting from 5% of femoral length proximal to distal epiphyseal growth plate and extended proximally for a total of 5% of femoral length. The trabecular bone was segmented from the bone marrow and analyzed to determine the trabecular bone volume fraction (BV/TV), trabecular thickness (Tb. Th), trabecular number (Tb. N) and trabecular separation (Tb. Sp). Diaphyseal cortical bone ROI was drawn starting from 20% of femoral length proximal to distal epiphyseal growth plate and extended proximally for a total of 10% of femoral length. We analyzed the cortical bone in order to determine the cortical thickness (Ct. Th), periosteal perimeter (Ps. Pm) and endosteal perimeter (Es. Pm).
Angiography. We used µCT for imaging bone blood vessels as previously described 65, 66 . Briefly, after euthanization of mice, the thoracic cavity was opened, a needle was inserted into the left ventricle, the vasculature was flushed with heparinized saline (0.9% normal saline containing 100 U ml −1 heparin sodium) and 10% neutral buffered formalin was injected for pressure fixation and then flushed from the vasculature using heparinized saline. Then, we injected a lead chromate-containing radiopaque silicone rubber compound (Microfil MV-122, Flow Tech.) into the vasculature. Mice were stored at 4 °C for 24 h and femora were then removed, fixed, decalcified and imaged by µCT. Vascular volume and surface area were measured.
Immunocytochemistry, immunofluorescence and histomorphometry. For immunocytochemical staining, we incubated cultured cells with primary antibody to mouse PDGF-BB (Abcam, ab21234, 1:50) at 37 °C for 2 h and subsequently used a horseradish peroxidase-streptavidin detection system (Dako) to detect the immunoreactivity, followed by TRAP staining using a staining kit (Sigma-Aldrich).
At the time of euthanasia, we dissected and fixed the femora with intact periosteum in 10% buffered formalin for 48 h, decalcified them in 10% EDTA (pH 7.4) (Amresco) for 21 d and embedded them in paraffin or optimal cutting temperature compound (Sakura Finetek). We processed four-micrometer-thick coronally (longitudinally) oriented sections of bone including the metaphysis and diaphysis for TRAP staining using a staining kit (Sigma-Aldrich). We performed immunofluorescence analysis of the bone sections as described previously 13, 64 . Briefly, we incubated bone sections with individual primary antibodies to mouse CD31 (Abcam, ab28364, 1:50), endomucin (Santa Cruz, V.7C7, 1:50), TRAP (Santa Cruz, sc-30833, 1:200), PDGF-BB (Abcam, ab21234, 1:50), Ki67 (Novus Biologicals, NB500-170, 1:50), osteocalcin (Takara, M173, 1:200) and F4/80 (Biolegend, BM8, 1:25) overnight at 4 °C. Subsequently, we used secondary antibodies conjugated with fluorescence at room temperature for 1 h while avoiding light. We used isotype-matched controls, such as polyclonal rabbit IgG (R&D Systems, AB-105-C), polyclonal goat IgG (R&D Systems, AB-108-C) and monoclonal rat IgG2A (R&D Systems, 54447) under the same concentrations and conditions as negative controls. We counted the numbers of positively stained cells in the whole diaphyseal periosteum or four random visual fields of distal metaphysis per femur in five sequential sections per mouse in each group and normalized them to the number per millimeter of adjacent bone surface (N mm −1 ) in trabecular and cortical bone or per square millimeter of bone marrow area (N mm −2 ) in trabecular bone. We used Leica TCS SP1 or SP2 confocal microscope or an Olympus BX51 Microscope for imaging samples.
To examine dynamic bone formation, we subcutaneously injected 0.1% calcein (Sigma, 10 mg kg −1 b.w.) in PBS into the mice 10 and 3 days before euthanization. We observed calcein double labeling in undecalcified bone slices under a fluorescence microscope. We measured periosteal bone formation at the site starting from 20% of femoral length proximal to distal epiphyseal growth plate and extended proximally for a total of 10% of femoral length. We measured trabecular bone formation in four randomly selected visual fields in distal metaphysis of femur.
Flow cytometry. For the analysis or sorting of CD31 hi Emcn hi cells and total ECs in bone, after euthanization of 1-month-old male mice, we collected femora and tibiae, removed epiphysis at the end and the muscles and periosteum around the bone, and then crushed the metaphysis and diaphysis regions of the bone in ice-cold PBS. We digested whole bone marrow with collagenase at 37 °C for 20 min to obtain single-cell suspensions. After filtration and washing, we counted cells and incubated equal numbers of cells for 45 min at 4 °C with fluorescein isothiocyanate-conjugated endomucin antibody (Santa Cruz, V.7C7, 1:20) for 45 min, then washed cells, and further incubated them with peridinin chlorophyll protein (PerCP)-conjugated CD31 antibody (Biolegend, 390, 1:100) for 45 min at 4 °C. We also incubated cells for 45 min at 4 °C with phycoerythrin-, PerCP-and allophycocyanin-conjugated antibodies to mouse CD31 (Biolegend, 390, 1:100), CD45 (Biolegend, 30-F11, 1:100) and Ter119 (Biolegend, TER-119, npg 1:100). We performed acquisition on a fluorescence-activated cell sorting (FACS) Aria model (BD Biosciences) and did the analysis using FACS DIVE software version 6.1.3 (BD Biosciences). We sorted CD31 + CD45 − Ter119 − cells as total bone marrow endothelial cells from total bone marrow cells. We collected sorted endothelial cells, as well as total bone marrow cells, in an ELISA lysis buffer solution and stored them at −80 °C until ELISA analysis.
Preparation of MSCs and EPCs.
After euthanization, we collected bone marrow cells from 6-week-old male wild-type mice and cultured them in α minimum essential medium (α-MEM, Mediatech, Inc.) containing 100 U ml −1 penicillin (Sigma-Aldrich), 100 µg ml −1 streptomycin sulfate (Sigma-Aldrich) and 20% lot-selected FBS (FBS, Atlanta Biologicals) at 37 °C in a 5% CO 2 humidified incubator. After 72 h, we removed non-adherent cells and cultured adherent cells for an additional 7 d with a single media change. Then, we incubated cell aliquots for 20 min at 4 °C with fluorescein isothiocyanate-, phycoerythrin-, peridinin chlorophyll protein-and allophycocyanin-conjugated antibodies to mouse CD29 (Biolegend, HMβ1-1, 1:50), Sca-1 (Biolegend, D7, 1:100), CD45 (Biolegend, 30-F11, 1:100) and CD11b (Biolegend, M1/70, 1:50). We performed acquisition on a FACSAria model (BD Biosciences), and did the analysis using FACSDIVA software version 6.1.3 (BD Biosciences). We sorted CD29 + Sca-1 + CD45 − CD11b − cells as mouse bone marrow MSCs and enriched them by further culture.
Late-stage outgrowth EPCs isolated from bone marrow of 7-to 8-week-old C57BL/6 mice were obtained from BioChain (7030031). These cells show expression of various endothelial markers, such as CD31, CD105, vascular endothelial growth factor receptor 1 and neuropilin-1, and have the spindle morphology common to EPCs. These cells are considered as late-stage EPCs since they are negative for CD133, an early-stage endothelial progenitor marker.
Preparation of conditioned media from preosteoclasts and osteoclasts. We prepared different types of conditioned media from preosteoclasts or osteoclasts. We harvested monocytes and macrophages from bone marrow of 6-week-old wild-type male mice by flushing the marrow space of femora and tibiae. We cultured the flushed bone marrow cells overnight on Petri dishes in α-MEM containing 10% FBS, 100 U ml −1 penicillin, 100 µg ml −1 streptomycin sulfate and 30 ng ml −1 M-CSF (R&D Systems Inc.). After discarding the adherent cells, we incubated floating cells with M-CSF (30 ng ml −1 ) in order to obtain pure monocytes and macrophages. Upon incubation of monocytes and macrophages with or without bovine cortical bone slices in 24-well plates (1 × 10 5 cells per well) with 30 ng ml −1 M-CSF and 60 ng ml −1 RANKL (PeproTech), all cells became preosteoclasts after a 3-d culture. Alternatively, fully mature multinucleated osteoclasts were formed after incubation with 30 ng ml −1 M-CSF and 200 ng ml −1 RANKL for 8 d. We detected TRAP activities of the cultured preosteoclasts and mature osteoclasts using a commercial kit (Sigma-Aldrich). At the end of induction, we harvested serum-containing conditioned medium from the preosteoclasts and mature osteoclasts. Serum-free conditioned media were also harvested after one more day culture with serum-free medium containing the same concentrations of M-CSF and RANKL. After a centrifugation (2,500 r.p.m. for 10 min at 4 °C), we aliquoted conditioned media and stored them at −80 °C. We used serum-free conditioned media for migration experiments and serum-containing conditioned media for osteogenic differentiation induction experiments. In some experiments, we added the neutralizing antibodies for certain factors including PDGF-AA (R&D, AF1055, 1 µg ml −1 ), PDGF-BB (Abcam, ab10845, 1 µg ml −1 ), TGF-β1 (R&D, 9016, 2 µg ml −1 ), TGF-β2 (R&D, AB-112-NA, 2 µg ml −1 ), TGF-β3 (R&D, 20724, 1 µg ml −1 ), IGF-1 (R&D, AF791, 2 µg ml −1 ), IGF-II (R&D, AF792, 1 µg ml −1 ), IgG (R&D, AB-108-C, 1 µg ml −1 ), as well as Noggin (BD Biosciences, 100 ng ml −1 ) to the conditioned media.
In vitro assays for migration of MSCs and EPCs. We assessed cell migration in Transwell 96-well plates (Corning Inc.) with 8-µm pore filters. Briefly, we seeded 1 × 10 4 /well MSCs or EPCs in the upper chambers and preincubated them with either vehicle, 20 µM AG1296 (a PDGFR inhibitor; Cayman Chemical), 30 µM LY294002 (a PI3K inhibitor; Cayman Chemical), 10 µM MK2206 (an Akt inhibitor; Sellechchem) or 2 µM Y15 (a FAK inhibitor; Sigma-Aldrich) for 1 h, then incubated them with conditioned medium from the preosteoclasts or bone resorption conditioned medium in the lower chambers for further 4 h, with the inhibitor or vehicle remained in the upper chambers. At the end of incubation, we fixed the cells with 10% formaldehyde for 30 min and then removed the cells on the upper surface of each filter with cotton swabs. We stained the cells that had migrated through the pores to the lower surface with crystal violet (Sigma-Aldrich) and quantified them by counting five random fields per well using a microscope (Olympus) at ×200 magnification.
Bone marrow supernatant collection. We exposed bone marrow of euthanized mice after cutting two ends of tibia and placed the samples for centrifugation for 15 min at 3,000 r.p.m. and 4 °C to obtain bone marrow supernatants, which we then stored at −80 °C until ELISA assay.
ELISA analysis. We performed osteocalcin or CTX ELISA analysis of serum using a mouse osteocalcin EIA kit (Biomedical Technologies Inc.) or a RatLaps EIA kit (Immunodiagnostic Systems). We performed CTX ELISA analysis of conditioned media using a CrossLaps for Culture ELISA kit (Immunodiagnosticsystems). We performed PDGF-BB or VEGF ELISA analysis of conditioned medium, serum or bone marrow supernatant using a Mouse/Rat PDGF-BB Quantikine ELISA kit or a Mouse VEGF Quantikine ELISA Kit (R&D Systems). We did all ELISA assays according to the manufacturers' instructions.
In vitro assays for tube formation by EPCs, MSCs or co-culture. We plated Matrigel (BD Biosciences) in 96-well culture plates and incubated at 37 °C to polymerize for 45 min. We then seeded EPCs (2 × 10 4 cells/well), MSCs (2 × 10 4 cells/well), or combined MSCs (1 × 10 4 cells/well) and EPCs (1 × 10 4 cells/well) on polymerized Matrigel in plates. We cultured the cells with conditioned medium collected from preosteoclasts or monocytes and macrophages culture system. After incubation at 37 °C for 4 h we observed tube formation by microscopy and measured the cumulative tube lengths. In some experiments, we added the neutralizing antibody for PDGF-BB described above to preosteoclastconditioned medium. In another set of experiments, we preincubated the cells with AG1296 (20 µM), LY294002 (30 µM), MK2206 (10 µM) or Y15 (2 µM), specific inhibitors for PDGFR, PI3K, Akt or FAK, respectively, for 1 h, before incubating them with the conditioned media.
Immunoprecipitation and immunoblotting.
We measured PDGF-BB concentrations in conditioned media by immunoprecipitation and immunoblotting analysis as described 67 . Briefly, for immunoprecipitation, we incubated conditioned media with PDGF-AA or PDGF-BB antibodies described below and then used protein GSepharose to absorb antigen-antibody complexes (Amersham Biosciences).
We separated immunoprecipitates or total cell lysates by SDS-PAGE and then blotted them on a polyvinylidene fluoride membrane (Bio-Rad Laboratories). We incubated the membranes with specific antibodies to PDGF-AA (R&D Systems, AF1055, 1:2,000), PDGF-BB (Abcam, ab10845, 1:1,000), p-PDGFR-β (Abcam, ab16864,1:2,000), PDGFR-β (Santa Cruz, sc-432, 1:1,000), p-PI3K (Cell Signaling, #4228, 1:1,000), PI3K (Cell Signaling, #4292, 1:1,000), p-Akt (Cell Signaling, 193H12, 1:1,000), Akt (Cell Signaling, 40D4, 1:2,000), p-FAK (Santa Cruz, sc-11765-R, 1:500), FAK (Santa Cruz, sc-932, 1:500), Sphk1 (Abcam, ab71700,1:500) or β-actin (Sigma-Aldrich, AC-15, 1:10,000), and then developed the blots by an enhanced chemiluminescence kit (Amersham Biosciences).
Measurement of S1P in conditioned medium. We processed conditioned media prepared as described above for mass spectrometry. We extracted S1P as previously described 48 . Briefly, we added 100 µl 3 N NaOH into the medium (1 ml) with addition of C17-S1P (100 pmol; internal standard) for alkalization, then mixed with 1 ml CHCl 3 , 1 ml CH 3 OH and 9 µl HCl. We centrifuged the mixture at 300g for 5 min to separate the alkaline aqueous phase containing S1P. We reextracted the organic phase with 0.5 ml methanol, 0.5ml 1 N NaCl and 50 µl 3 N NaOH. We acidified the collected aqueous phases with 100 µl concentrated HCl and extracted the dephosphorylated sphingosine extracted twice with 1.5 ml CHCl 3 each. We then dried the combined CHCl 3 phases under vacuum and resuspended them in 200 µl CH 3 OH. We performed sample analysis using Voyager DE-STR mass spectrometer (Applied Biosystems).
Assessment of osteogenic differentiation of MSCs.
We seeded MSCs at a density of 5 × 10 3 cm −2 with serum-containing conditioned media from npg preosteoclast cultures. Serum-containing conditioned medium from monocyte and macrophage cultures served as a control. After 2 d of culture, we homogenized the cells and assayed ALP activity by spectrophotometric measurement of p-nitrophenol release using an enzymatic colorimetric ALP Kit (Roche) . After 3 weeks of culture, we evaluated the cell matrix mineralization by alizarin red S staining (2% of alizarin red S (Sigma-Aldrich) dissolved in distilled water with the pH adjusted to 4.2). Alizarin red S staining was released by cetyl-pyridinium chloride (Sigma-Aldrich) and quantified by spectrophotometry. To normalize protein expression to total cellular protein, an aliquot of the cell lysates was measured with the Bradford protein assay.
Statistical analyses. All error bars are s.d. Data presented as mean ± s.d. We used unpaired, two-tailed Student's t-tests for comparisons between two groups and one-way analysis of variance (ANOVA) with Bonferroni post hoc test for multiple comparisons. All data demonstrated a normal distribution and similar variation between groups. For all experiments, P < 0.05 were considered to be significant and indicated by '*'; P < 0.01 were indicated by '**' . All inclusion/exclusion criteria were preestablished and no samples or animals were excluded from the analysis. No statistical method was used to predetermine the sample size. The experiments were randomized. The investigators were not blinded to allocation during experiments and outcome assessment.
